This is a preview of subscription content, log in via an institution to check access.
Notes
The study was supported in part by Actelion Australia, Bayer, CLS Biotherapies, GlaxoSmithKline Australia and Pfizer.
Reference
Tran-Duy A, et al. Cost-Effectiveness of Combination Therapy for Patients With Systemic Sclerosis-Related Pulmonary Arterial Hypertension. Journal of the American Heart Association : 24 Mar 2021. Available from: URL: https://doi.org/10.1161/JAHA.119.015816
Rights and permissions
About this article
Cite this article
Combination therapy in systemic sclerosis-related pulmonary arterial hypertension: survival benefits at high cost. PharmacoEcon Outcomes News 875, 4 (2021). https://doi.org/10.1007/s40274-021-7583-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7583-5